GlassScriptPhysician profile
Katie Salyers
NPI 1972123826
$2,622.34
in general payments reported to CMS, 2019-2025
27 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $1,294 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $386.96 | 2024-2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $282.83 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $280.92 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $275.22 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $249.61 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $185.75 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.99 | 2024-2025 | Caplyta |
| Grifols USA, LLC | $168.12 | 2024-2025 | Prolastin-C Liquid |
| Dexcom, INC. | $71.28 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $53.23 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $50.09 | 2024 | Voquezna |
| Harmony Biosciences LLC | $48.26 | 2025 | |
| Baxter Healthcare | $47.31 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $42.68 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $38.02 | 2024-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $36.78 | 2025 | Ohtuvayre |
| Collegium Pharmaceutical, INC. | $35.59 | 2025 | Jornay Pm |
| Amgen INC. | $29.74 | 2024 | Evenity, Prolia |
| Edwards Lifesciences Corporation | $24.52 | 2024 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $24.07 | 2025 | Inspire |
| Lundbeck LLC | $20.14 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $18.84 | 2025 | Vpriv |
| Merck Sharp & Dohme LLC | $17.91 | 2024 | Gardasil 9, Gardasil, Vaxelis |
| Smith+Nephew, INC. | $17.40 | 2025 | Collagenase Santyl |
| Heartflow, INC. | $13.91 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.71 | 2024 | Jardiance |
| Ironshore Pharmaceuticals INC. | $13.46 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Salyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.